+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Contraceptive Drug Eluting Devices Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Contraceptive Drug Eluting Devices Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Contraceptive Drug Eluting Devices Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6078287
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Executive Overview of Contraceptive Drug-Eluting Devices Market Landscape

The contraceptive drug-eluting devices market stands at the intersection of biomedical innovation and public health imperatives, driven by an imperative to offer safe, effective, and long-acting contraceptive solutions. Over the past decade, implantable devices and intrauterine systems have evolved significantly, integrating advanced polymers, metallic alloys, and targeted drug formulations to enhance patient outcomes and minimize side effects. This evolution reflects a broader trend toward personalized medicine and patient-centric care, as healthcare providers and regulators increasingly demand devices that adapt to diverse physiological and lifestyle needs. As shifting demographics, technological breakthroughs, and regulatory recalibrations converge, stakeholders across R&D, manufacturing, and distribution must navigate a rapidly changing landscape. This introduction sets the stage for a deeper exploration of transformative shifts, tariff influences, segmentation nuances, regional dynamics, competitive strategies, and actionable recommendations. By examining each facet in detail, decision-makers will gain a comprehensive understanding of the forces shaping current market dynamics and how to leverage emerging opportunities. Ultimately, this executive summary offers a concise yet thorough roadmap for pharma executives, device manufacturers, and policy leaders seeking to stay ahead in this critical healthcare segment.

Transformative Shifts Driving Next-Generation Contraceptive Devices

Innovation in drug-eluting contraceptive systems has accelerated over recent years, reshaping both clinical practice and commercial strategies. Medical device designers have harnessed biodegradable polymers and biocompatible alloys to achieve controlled, sustained release of hormones and non-hormonal agents, thereby reducing the frequency of insertion and removal procedures. Concurrently, digital health platforms have begun to augment device monitoring, enabling clinicians to track adherence and physiological responses in near real time. This digital integration dovetails with a growing emphasis on patient engagement, as healthcare providers offer mobile apps and telehealth consultations to support users throughout their contraceptive journey.

Regulatory bodies have also adapted, streamlining pathways for next-generation implants and intrauterine devices while enforcing rigorous post-market surveillance to ensure safety. Emerging economies are fast adopting these advancements, driven by government-led reproductive health initiatives and rising awareness of long-acting reversible contraceptives. Furthermore, competitive dynamics are fostering collaborations between traditional pharmaceutical companies and medtech startups, creating hybrid business models that blend formulation expertise with device engineering. As a result, market entrants that can balance regulatory compliance, technological prowess, and patient-centric services will capture significant share. Consequently, stakeholders must anticipate rapid product cycles, strategic alliances, and evolving reimbursement policies to maintain a leadership position.

Cumulative Impact of US Tariffs on Contraceptive Device Manufacturing

In 2025, the introduction of cumulative United States tariffs on imported raw materials and finished medical devices has significantly influenced supply chain programs and cost structures. The levies, targeting key inputs such as titanium alloys, nickel-based components, and specialized polymers, have prompted manufacturers to reassess sourcing strategies. In response, many companies have relocated part of their production footprint back to North America, forging new partnerships with domestic suppliers and subcontractors. This reshoring trend ensures tariff avoidance and mitigates logistical complexities associated with fluctuating trade policies.

Moreover, increased sourcing from regional free trade partners has emerged as a tactical countermeasure, leveraging tariff exemptions under existing agreements. Companies that proactively diversified their procurement pipelines achieved greater resilience against price volatility. However, these supply chain adjustments have also introduced challenges, including capacity constraints among domestic alloy producers and longer qualification timelines for polymer suppliers. Consequently, organizations are investing in supplier development programs, co-innovation agreements, and shared-risk contracts to secure consistent material flows.

From a commercial standpoint, device manufacturers have engaged in pricing recalibrations to offset tariff-induced cost inflation while preserving market accessibility. Collaborative efforts with payers and healthcare systems to establish value-based contracting mechanisms have softened potential headwinds, ensuring that advances in contraceptive technology remain within reach for end-users.

Key Segmentation Insights Shaping Development and Adoption

A nuanced understanding of market segmentation reveals critical pathways for targeted innovation and commercial outreach. When assessed by product type, implantable devices split into hormonal and non-hormonal options, each catering to distinct patient preferences; hormonal contraceptive implants further differentiate into reversible and non-reversible formats, while non-hormonal implants employ either copper or advanced polymer matrices. Intrauterine devices similarly bifurcate into hormonal versions, available in ring-like and T-shaped frames, and non-hormonal options that leverage either copper or inert materials.

Material considerations further refine this landscape: metals such as nickel-based and titanium alloys offer structural integrity and biocompatibility, whereas polymers range from biodegradable PGA and PLA to non-degradable polystyrene and PTFE variants. Each material class presents unique release kinetics and safety profiles. Drug formulation also plays a pivotal role, with combination therapies integrating estrogen and progestin, alongside standalone estrogen or progestin options derived from natural and synthetic sources.

Beyond product architecture, demographic segmentation underscores varying adoption rates across life stages. Adolescents aged 10-14 and 15-19 exhibit different counseling and compliance needs compared to adults in the 20-34 and 35-49 brackets, while middle-aged users aged 50-64 and those over 65 prioritize long-term effect monitoring. Finally, prescription status delineates over-the-counter accessibility from prescription-only channels, the latter subdivided into general practitioner and specialist prescriptions, reflecting the interplay of regulatory frameworks and clinical oversight.

Key Regional Insights Driving Market Dynamics

Regional dynamics exert a profound influence on market momentum and strategic focus. In the Americas, robust public health initiatives and established reimbursement systems underlie steady adoption of long-acting reversible contraceptives, with the United States serving as both an innovation hub for implantable and intrauterine devices and a major consumer market. Latin American countries, buoyed by awareness campaigns and expanding insurance coverage, are closing the gap in device penetration even as cost and infrastructure barriers remain.

Meanwhile, in Europe, Middle East & Africa, regulatory harmonization across the European Union streamlines approvals for novel devices, while emerging markets in the Middle East and North Africa demonstrate growing demand driven by shifting cultural attitudes and government-supported family planning programs. Variability in healthcare infrastructure, however, demands adaptable cost structures and targeted patient education efforts. In sub-Saharan Africa, partnerships between nonprofit organizations and local distributors facilitate outreach to underserved populations.

Asia-Pacific stands out for its dual character: highly advanced markets in Japan, South Korea, and Australia adopt cutting-edge polymeric and digital-integrated platforms, whereas rapidly developing economies in Southeast Asia and India prioritize scalable, cost-effective IUD solutions. Local manufacturers in the region are increasingly collaborating with global device and drug developers to co-create offerings optimized for regional clinical and economic contexts.

Key Company Profiles and Competitive Strategies

Competitive dynamics reflect a blend of legacy pharmaceutical leaders, specialized device innovators, and mission-driven organizations. Bayer AG continues to leverage its broad contraceptive portfolio, integrating drug-eluting implants with digital adherence tools, while Allergan under AbbVie applies its deep regulatory expertise to secure accelerated approvals in multiple jurisdictions. Teva Pharmaceutical Industries and Merck & Co. reinforce their positions through strategic acquisitions of niche startups focused on next-generation polymers and hormone analogues.

Meanwhile, Agile Therapeutics and Pathfinder Therapeutics drive niche segments with disruptive delivery platforms designed for rapid insertion and minimal side effects. Companies like FemHealth USA, now part of a broader FemTech Health portfolio, focus on patient-centric service models that blend telehealth support with device-centric care pathways. HRA Pharma, under Perrigo, and Population Council introduce nonprofit frameworks that prioritize access and affordability, particularly in emerging markets.

Boehringer Ingelheim and Organon & Co. invest heavily in R&D collaborations to expand pipelines for novel progestin-based systems, while Revive Therapeutics and The Cooper Companies explore biocompatible polymer coatings and smart sensors to differentiate their offerings. This competitive tapestry underscores the need for continuous innovation, strategic partnerships, and patient engagement strategies to secure sustainable growth.

Actionable Recommendations for Industry Leaders

To thrive amid technological advances, tariff pressures, and shifting patient expectations, industry leaders should pursue several strategic initiatives. First, diversifying raw material sources through multi-regional partnerships can mitigate exposure to trade disruptions and ensure consistent quality standards. Second, accelerating research into biodegradable polymer matrices will align device lifecycles with sustainable healthcare mandates and patient preferences for fewer follow-up procedures. Third, integrating digital adherence monitoring and telehealth support into contraceptive platforms will enhance patient engagement, reduce discontinuation rates, and capture valuable real-world data.

In parallel, stakeholders should strengthen collaborations with regulatory authorities to shape adaptive approval pathways, expedite post-market surveillance, and advocate for value-based reimbursement models that recognize both clinical efficacy and user convenience. Expanding outreach in underserved regions requires flexible pricing structures and alliances with nonprofit organizations to bridge access gaps. Lastly, fostering open innovation through academic partnerships, incubator programs, and cross-industry consortia will fuel breakthroughs in drug formulation, device engineering, and patient experience design. By executing these recommendations in a coordinated manner, organizations can secure competitive advantage and drive sustainable growth.

Conclusion: Navigating Complexity Through Innovation and Collaboration

In summary, the contraceptive drug-eluting device market is characterized by rapid innovation, evolving regulatory landscapes, and complex supply chain dynamics. Technological breakthroughs in materials science and digital health are converging to deliver personalized, long-acting contraceptive solutions that meet diverse patient needs. Meanwhile, tariff-induced cost pressures and shifting regional demand patterns necessitate agile sourcing strategies and adaptive commercial models. By aligning segmentation-driven product development with targeted regional approaches and collaborative competitive tactics, market participants can navigate emerging challenges and capitalize on growth opportunities. The path forward hinges on continuous investment in R&D, strategic partnerships across the value chain, and unwavering focus on patient-centric outcomes. As the market advances, organizations that integrate sustainability, digital connectivity, and localized engagement into their core strategies will emerge as the next generation of market leaders.

Market Segmentation & Coverage

This research report categorizes the Contraceptive Drug Eluting Devices Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Implantable Devices
    • Hormonal Contraceptive Implants
      • Non-Reversible Hormonal Implants
      • Reversible Hormonal Implants
    • Non-Hormonal Contraceptive Implants
      • Copper-Based Implants
      • Polymer-Based Implants
  • Intrauterine Devices
    • Hormonal IUDs
      • Ring-Like IUDs
      • T-Like Frame IUDs
    • Non-Hormonal IUDs
      • Copper IUDs
      • Inert IUDs
  • Metals
    • Nickel-Based Alloys
    • Titanium Alloys
  • Polymers
    • Biodegradable Polymers
      • PGA (Polyglycolic Acid)
      • PLA (Polylactic Acid)
    • Non-Biodegradable Polymers
      • Polystyrene
      • PTFE (Polytetrafluoroethylene)
  • Combination Drugs
    • Alternative Combination Drugs
    • Estrogen-Progestin Combination
  • Estrogen-Based Drugs
    • Natural Estrogen
    • Synthetic Estrogen
  • Progestin-Based Drugs
    • Natural Progestins
    • Synthetic Progestins
  • Adolescents
    • 10-14 Years
    • 15-19 Years
  • Adults
    • 20-34 Years
    • 35-49 Years
  • Middle-Aged and Seniors
    • 50-64 Years
    • 65+ Years
  • Over-The-Counter
  • Prescription-Based
    • GP Prescription
    • Specialist Prescription

This research report categorizes the Contraceptive Drug Eluting Devices Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Contraceptive Drug Eluting Devices Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Agile Therapeutics, Inc.
  • Allergan (a part of AbbVie)
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • FemHealth USA, Inc. (now a subsidiary of FemTech Health)
  • HRA Pharma (a subsidiary of Perrigo Company plc)
  • Merck & Co., Inc.
  • Organon & Co.
  • Pathfinder Therapeutics, Inc.
  • Population Council (Nonprofit NGO)
  • Revive Therapeutics Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Cooper Companies, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Contraceptive Drug Eluting Devices Market, by Product Type
8.1. Introduction
8.2. Implantable Devices
8.2.1. Hormonal Contraceptive Implants
8.2.1.1. Non-Reversible Hormonal Implants
8.2.1.2. Reversible Hormonal Implants
8.2.2. Non-Hormonal Contraceptive Implants
8.2.2.1. Copper-Based Implants
8.2.2.2. Polymer-Based Implants
8.3. Intrauterine Devices
8.3.1. Hormonal IUDs
8.3.1.1. Ring-Like IUDs
8.3.1.2. T-Like Frame IUDs
8.3.2. Non-Hormonal IUDs
8.3.2.1. Copper IUDs
8.3.2.2. Inert IUDs
9. Contraceptive Drug Eluting Devices Market, by Material Type
9.1. Introduction
9.2. Metals
9.2.1. Nickel-Based Alloys
9.2.2. Titanium Alloys
9.3. Polymers
9.3.1. Biodegradable Polymers
9.3.1.1. PGA (Polyglycolic Acid)
9.3.1.2. PLA (Polylactic Acid)
9.3.2. Non-Biodegradable Polymers
9.3.2.1. Polystyrene
9.3.2.2. PTFE (Polytetrafluoroethylene)
10. Contraceptive Drug Eluting Devices Market, by Drug Type
10.1. Introduction
10.2. Combination Drugs
10.2.1. Alternative Combination Drugs
10.2.2. Estrogen-Progestin Combination
10.3. Estrogen-Based Drugs
10.3.1. Natural Estrogen
10.3.2. Synthetic Estrogen
10.4. Progestin-Based Drugs
10.4.1. Natural Progestins
10.4.2. Synthetic Progestins
11. Contraceptive Drug Eluting Devices Market, by Age Group
11.1. Introduction
11.2. Adolescents
11.2.1. 10-14 Years
11.2.2. 15-19 Years
11.3. Adults
11.3.1. 20-34 Years
11.3.2. 35-49 Years
11.4. Middle-Aged and Seniors
11.4.1. 50-64 Years
11.4.2. 65+ Years
12. Contraceptive Drug Eluting Devices Market, by Prescription Status
12.1. Introduction
12.2. Over-The-Counter
12.3. Prescription-Based
12.3.1. GP Prescription
12.3.2. Specialist Prescription
13. Americas Contraceptive Drug Eluting Devices Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Contraceptive Drug Eluting Devices Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Contraceptive Drug Eluting Devices Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Agile Therapeutics, Inc.
16.3.2. Allergan (a part of AbbVie)
16.3.3. Bayer AG
16.3.4. Boehringer Ingelheim GmbH
16.3.5. FemHealth USA, Inc. (now a subsidiary of FemTech Health)
16.3.6. HRA Pharma (a subsidiary of Perrigo Company plc)
16.3.7. Merck & Co., Inc.
16.3.8. Organon & Co.
16.3.9. Pathfinder Therapeutics, Inc.
16.3.10. Population Council (Nonprofit NGO)
16.3.11. Revive Therapeutics Ltd.
16.3.12. Teva Pharmaceutical Industries Ltd.
16.3.13. The Cooper Companies, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CONTRACEPTIVE DRUG ELUTING DEVICES MARKET MULTI-CURRENCY
FIGURE 2. CONTRACEPTIVE DRUG ELUTING DEVICES MARKET MULTI-LANGUAGE
FIGURE 3. CONTRACEPTIVE DRUG ELUTING DEVICES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CONTRACEPTIVE DRUG ELUTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-REVERSIBLE HORMONAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REVERSIBLE HORMONAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COPPER-BASED IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMER-BASED IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY RING-LIKE IUDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY T-LIKE FRAME IUDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COPPER IUDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INERT IUDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NICKEL-BASED ALLOYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TITANIUM ALLOYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PGA (POLYGLYCOLIC ACID), BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA (POLYLACTIC ACID), BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYSTYRENE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PTFE (POLYTETRAFLUOROETHYLENE), BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ALTERNATIVE COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-PROGESTIN COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NATURAL ESTROGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SYNTHETIC ESTROGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NATURAL PROGESTINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SYNTHETIC PROGESTINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY 10-14 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY 15-19 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY 20-34 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY 35-49 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY 50-64 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY 65+ YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GP PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALIST PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 141. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 143. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 144. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 145. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 146. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 147. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 148. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 149. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 150. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 151. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 152. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 153. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 155. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 156. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 157. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 159. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 160. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 161. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 162. CANADA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 163. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 165. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 168. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 169. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 175. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 177. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 178. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 253. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 255. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 256. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 257. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 258. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 259. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 260. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 261. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 262. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 263. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 264. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 265. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 267. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ESTROGEN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 268. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PROGESTIN-BASED DRUGS, 2018-2030 (USD MILLION)
TABLE 269. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 271. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 272. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MIDDLE-AGED AND SENIORS, 2018-2030 (USD MILLION)
TABLE 273. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2030 (USD MILLION)
TABLE 274. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
TABLE 275. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2030 (USD MILLION)
TABLE 277. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 278. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL CONTRACEPTIVE IMPLANTS, 2018-2030 (USD MILLION)
TABLE 279. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2030 (USD MILLION)
TABLE 280. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 281. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-HORMONAL IUDS, 2018-2030 (USD MILLION)
TABLE 282. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY METALS, 2018-2030 (USD MILLION)
TABLE 284. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY POLYMERS, 2018-2030 (USD MILLION)
TABLE 285. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 286. INDIA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS,

Companies Mentioned

  • Agile Therapeutics, Inc.
  • Allergan (a part of AbbVie)
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • FemHealth USA, Inc. (now a subsidiary of FemTech Health)
  • HRA Pharma (a subsidiary of Perrigo Company plc)
  • Merck & Co., Inc.
  • Organon & Co.
  • Pathfinder Therapeutics, Inc.
  • Population Council (Nonprofit NGO)
  • Revive Therapeutics Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Cooper Companies, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Contraceptive Drug Eluting Device Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Contraceptive Drug Eluting Device Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From
Implantable Drug Delivery Devices Market Report 2025 - Product Image

Implantable Drug Delivery Devices Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Hormonal Contraceptive Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Hormonal Contraceptive Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Implantable Drug Delivery Devices Market 2025-2033 - Product Image

Implantable Drug Delivery Devices Market 2025-2033

  • Report
  • 144 Pages
  • Global
From
U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2024 - 2030 - Product Image

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2024 - 2030

  • Report
  • 113 Pages
  • United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.